Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab

Abstract

AbstractBackgroundDupilumab is approved for moderate‐severe atopic dermatitis (AD) in patients aged ≥6 months by the US Food and Drug Administration and Health Canada; however, there are little real‐world data because providers have limited practical experience with this recently approved therapy.ObjectivesTo describe the real‐world effectiveness and safety in patients aged <12 years with moderate‐severe AD currently receiving or previously having received dupilumab.MethodsA multicenter retrospective study was conducted at six Canadian sites. Cases were divided into Group 1 ≤2 years old, Group 2 >2 to <6 years old, and Group 3 ≥6 to <12 years old. Medical history and details of dupilumab treatment were collected. The primary outcome was to measure the improvement in eczema area and severity index. Secondary outcomes examined included the children's dermatology life quality index/infant's dermatitis quality of life, peak pruritus numerical rating scale, and delay to dupilumab access for patients who were considered off‐label for dupilumab due to their age.ResultsSixty three pediatric patients (37 males) with moderate‐to‐severe AD were included; the mean age was 6.4 years old (range: 2–11) when dupilumab treatment was started. Overall, 75% (36/48) achieved EASI‐75% and 71% (34/48) achieved EASI‐90. EASI‐75 and EASI‐90 were achieved in 90% (17/19) and 73% (12/19) in patients <6 years old, and 76% (22/29) and 59% (17/29) in patients >6 years old, respectively. No serious adverse events were reported.ConclusionsDupilumab is safe and effective for patients under the age of 12. However, even for experienced providers, access to the medication was challenging.